At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 47 enrolled
Drug / intervention
MDNA55drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
In Brief
A Phase 2 clinical trial evaluating MDNA55 for Glioblastoma and 3 related conditions. Completed, enrolled 47 participants across 7 sites.
Detailed Summary
This is a single-arm, open-label, multicenter study in approximately 52 adults with primary (de novo) GB that has recurred or progressed (first or second recurrence, including this recurrence) after treatment(s) including surgery and radiotherapy with or without chemotherapy and following discontinuation of any previous standard or investigational lines of therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartApr 2017
Primary CompletionSep 2019
Study CompletionOct 2019
TodayJul 2026
First PostedAug 8, 2016
Enrollment StartApr 11, 2017
Primary CompletionSep 12, 2019
Study CompletionOct 31, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.9 years ago
Interventions
MDNA55drug
MDNA55 is an engineered circularly permuted interleukin-4 (cpIL-4) genetically fused to the catalytic domain of the pseudomonas exotoxin A (PE).